Fatemeh Mortazavi Moghadam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fatemeh Mortazavi Moghadam has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Marjan Ghorbani
5 shared publicationsMastafa H. Al-Musawi
5 shared publications- Mohammad Reza Bigdeli
Department of Animal Sciences and Marine Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
5 shared publications Fatemeh Doustdar
3 shared publications- Marjan Ghorbani
Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications Soghra Ramezani
3 shared publications
Latest Publications
- 30 September 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32, 1-10
Conferone: Sources, Anticancer Mechanisms, and Potential in Overcoming Chemoresistance - A Comprehensive Review
Introduction: Cancer remains a leading cause of mortality worldwide, and limitations of conventional therapies such as toxicity and Multidrug Resistance (MDR) highlight the need for safer and more effective agents. Natural compounds derived from medicinal plants have gained attention as potential anticancer therapeutics. Conferone, a sesquiterpene coumarin isolated mainly from Ferula species, has shown promising biological activities. Methods: This review comprehensively summarizes available primarily in vitro studies, with very limited in vivo evidence investigating the anticancer properties of conferone. Data were collected from published experimental studies focusing on its chemical characteristics, pharmacological effects, molecular mechanisms, and efficacy across different cancer cell lines. Results: Conferone exhibits significant anticancer activity against a wide range of malignancies, including leukemia/lymphoma, breast, colorectal, bladder, ovarian, and embryonal cancers. Its mechanisms involve induction of mitochondrial-dependent apoptosis, cell cycle arrest, increased oxidative stress, inhibition of angiogenesis, and modulation of oncogenic signaling pathways such as NF-κB, c-MYC, and CDK6. Notably, conferone exhibits MDR-modulating activity by inhibiting ATP-binding cassette transporters (e.g., P-gp and MRP2), thereby enhancing intracellular accumulation and efficacy of chemotherapeutic agents like doxorubicin, vincristine, and cisplatin. Incorporation into nanocarrier-based delivery systems further improves its bioavailability and anticancer potency. Conclusion: Conferone is a multifunctional natural compound with strong anticancer and chemosensitizing properties. Although current findings are encouraging, further in vivo and clinical investigations are required to clarify its pharmacokinetics, safety profile, and therapeutic potential in cancer treatment.
- 30 September 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32, 1-10
Conferone: Sources, Anticancer Mechanisms, and Potential in Overcoming Chemoresistance - A Comprehensive Review
Introduction: Cancer remains a leading cause of mortality worldwide, and limitations of conventional therapies such as toxicity and Multidrug Resistance (MDR) highlight the need for safer and more effective agents. Natural compounds derived from medicinal plants have gained attention as potential anticancer therapeutics. Conferone, a sesquiterpene coumarin isolated mainly from Ferula species, has shown promising biological activities. Methods: This review comprehensively summarizes available primarily in vitro studies, with very limited in vivo evidence investigating the anticancer properties of conferone. Data were collected from published experimental studies focusing on its chemical characteristics, pharmacological effects, molecular mechanisms, and efficacy across different cancer cell lines. Results: Conferone exhibits significant anticancer activity against a wide range of malignancies, including leukemia/lymphoma, breast, colorectal, bladder, ovarian, and embryonal cancers. Its mechanisms involve induction of mitochondrial-dependent apoptosis, cell cycle arrest, increased oxidative stress, inhibition of angiogenesis, and modulation of oncogenic signaling pathways such as NF-κB, c-MYC, and CDK6. Notably, conferone exhibits MDR-modulating activity by inhibiting ATP-binding cassette transporters (e.g., P-gp and MRP2), thereby enhancing intracellular accumulation and efficacy of chemotherapeutic agents like doxorubicin, vincristine, and cisplatin. Incorporation into nanocarrier-based delivery systems further improves its bioavailability and anticancer potency. Conclusion: Conferone is a multifunctional natural compound with strong anticancer and chemosensitizing properties. Although current findings are encouraging, further in vivo and clinical investigations are required to clarify its pharmacokinetics, safety profile, and therapeutic potential in cancer treatment.
- 17 May 2026
- Published by Elsevier in Experimental Neurology
- Vol. 403, 115837
Spinal cord injury as a window into hippocampal dysfunction: Linking inflammation, neurogenesis, and network oscillations to cognitive decline
- 17 May 2026
- Published by Elsevier in Experimental Neurology
- Vol. 403, 115837
Spinal cord injury as a window into hippocampal dysfunction: Linking inflammation, neurogenesis, and network oscillations to cognitive decline
- 21 April 2026
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 21 (1) , 22
Targeting Neuroinflammation in the Piriform Cortex-Amygdala: Enhanced Efficacy of Niosome-Based Sodium Butyrate in Ischemic Stroke
- 21 April 2026
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 21 (1) , 22
Targeting Neuroinflammation in the Piriform Cortex-Amygdala: Enhanced Efficacy of Niosome-Based Sodium Butyrate in Ischemic Stroke
- 6 March 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 696, 126746
Microneedle dressing incorporating deferoxamine-loaded silk fibroin nanoparticles for diabetic wound therapy
- 6 March 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 696, 126746
Microneedle dressing incorporating deferoxamine-loaded silk fibroin nanoparticles for diabetic wound therapy
- Top Cited PapersOpen Access
- 21 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (6) , 5088-5127
Self-assembling nanocomposites for smart drug delivery: towards personalized and stimuli-responsive therapeutics
Self-assembling nanocomposites (SANCs) represent a valuable and innovative drug delivery system that facilitates site-specific and stimulus-controlled drug administration.
- 21 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (6) , 5088-5127
Top Cited PapersOpen AccessSelf-assembling nanocomposites for smart drug delivery: towards personalized and stimuli-responsive therapeutics
Self-assembling nanocomposites (SANCs) represent a valuable and innovative drug delivery system that facilitates site-specific and stimulus-controlled drug administration.
- Open Access
- 15 January 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 235, 111736
Niosome-encapsulated sodium butyrate enhances blood-brain barrier integrity and reduces neuroinflammation in a rat model of ischemic stroke
- 15 January 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 235, 111736
Open AccessNiosome-encapsulated sodium butyrate enhances blood-brain barrier integrity and reduces neuroinflammation in a rat model of ischemic stroke
- 28 July 2025
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 113 (8) , e35625
Propolis‐Infused Electrospun Eudragit/PVP Mats: A Novel Approach for Bioactive and Antibacterial Wound Dressings
Electrospun mats with varying ratios of Eudragit L‐100 (EU) to polyvinylpyrrolidone (PVP) were fabricated and characterized. Morphological analysis (FESEM), fiber diameter distribution, porosity measurements, degradability studies, and water vapor transmission rate (WVTR) assessments indicated that an EU/PVP ratio of 70:30 exhibited optimal properties. Propolis (PRO), known for its antimicrobial, antioxidant, and anti‐inflammatory effects, was incorporated into the optimized mats at different weight percentages (5, 10, and 20 wt%). The inclusion of PRO resulted in increased fiber thickness and decreased porosity. PRO‐loaded mats exhibited lower degradation rates and slightly enhanced tensile strength compared to the neat EU/PVP mats. A higher PRO content led to a reduction in WVTR, while radical scavenging activity increased to over 40%. Hemocompatibility and biocompatibility were confirmed through hemolysis tests, cell proliferation assays, cell attachment studies, and live/dead staining. Additionally, PRO‐loaded mats exhibited antibacterial efficacy against Escherichia coli and Staphylococcus aureus. The sustained release of PRO from the EU/PVP matrix further supports its potential as an effective wound dressing.
- 28 July 2025
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 113 (8) , e35625
Propolis‐Infused Electrospun Eudragit/PVP Mats: A Novel Approach for Bioactive and Antibacterial Wound Dressings
Electrospun mats with varying ratios of Eudragit L‐100 (EU) to polyvinylpyrrolidone (PVP) were fabricated and characterized. Morphological analysis (FESEM), fiber diameter distribution, porosity measurements, degradability studies, and water vapor transmission rate (WVTR) assessments indicated that an EU/PVP ratio of 70:30 exhibited optimal properties. Propolis (PRO), known for its antimicrobial, antioxidant, and anti‐inflammatory effects, was incorporated into the optimized mats at different weight percentages (5, 10, and 20 wt%). The inclusion of PRO resulted in increased fiber thickness and decreased porosity. PRO‐loaded mats exhibited lower degradation rates and slightly enhanced tensile strength compared to the neat EU/PVP mats. A higher PRO content led to a reduction in WVTR, while radical scavenging activity increased to over 40%. Hemocompatibility and biocompatibility were confirmed through hemolysis tests, cell proliferation assays, cell attachment studies, and live/dead staining. Additionally, PRO‐loaded mats exhibited antibacterial efficacy against Escherichia coli and Staphylococcus aureus. The sustained release of PRO from the EU/PVP matrix further supports its potential as an effective wound dressing.